Anna Dimberg

Anna Dimberg is Professor at Uppsala University's Department of Immunology, Genetics and Pathology, where she leads the Vascular Biology research program. Her laboratory investigates tumor vascular abnormalities in cancers, with particular emphasis on glioblastoma. The research examines how altered vessel phenotypes influence tumor microenvironments and therapy responses, focusing on endothelial cell biology and vascular-immune interactions.

Her research integrates multiple approaches:

• Molecular characterization of tumor endothelial cells using single-cell RNA sequencing
• Development of vascular normalization strategies to improve immunotherapy
• Investigation of endothelial-immune cell crosstalk in tumor progression
• AAV-based gene therapies to remodel tumor vasculature
• Patient-derived iPSC models of vascular disorders

Publication analysis reveals consistent focus on vascular biology mechanisms in cancer contexts. Recent work emphasizes: vascular checkpoint targets (CD93, ELTD1), immunotherapy combination strategies, endothelial barrier regulation, and single-cell characterization of tumor vasculature. The research has progressively incorporated spatial transcriptomics and advanced immune profiling techniques since 2020.

The laboratory maintains active collaborations as evidenced by multi-institutional publications and investigates both fundamental vascular biology mechanisms and translational applications for cancer therapy.